Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alimera, pSivida win FDA nod for Iluvien, finally

This article was originally published in Scrip

Executive Summary

Shares of Alimera and pSivida continued to rise in premarket trading on 29 September after jumping in after-hours trading on 26 September when they revealed the FDA had finally granted its approval to Iluvien (fluocinolone acetonide intravitreal implant) as a treatment for diabetic macular edema (DME) in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.


Related Content

Early Yutiq Approval Gives EyePoint Two Ophthalmic Drugs To Launch In 2019


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts